Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116


The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family.

Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E.

Cell. 1995 Feb 10;80(3):389-99.


Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors.

Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, Rowe M, Young LS.

Oncogene. 1997 Jun 19;14(24):2899-916.


A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways.

Adriaenssens E, Mougel A, Goormachtigh G, Loing E, Fafeur V, Auriault C, Coll J.

Oncogene. 2004 Apr 8;23(15):2681-93. Erratum in: Oncogene. 2004 Oct 21;23(49):8184.


Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas.

Murray PG, Swinnen LJ, Flavell JR, Ragni MV, Baumforth KR, Toomey SM, Filipovich AH, Lowe D, Schnell CS, Johl J, Gulley M, Young LS, Ambinder RF.

Hum Pathol. 2001 Sep;32(9):963-9.


LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3.

Wu S, Xie P, Welsh K, Li C, Ni CZ, Zhu X, Reed JC, Satterthwait AC, Bishop GA, Ely KR.

J Biol Chem. 2005 Sep 30;280(39):33620-6. Epub 2005 Jul 11.


Mechanism of action of a novel latent membrane protein-1 dominant negative.

Brennan P, Floettmann JE, Mehl A, Jones M, Rowe M.

J Biol Chem. 2001 Jan 12;276(2):1195-203.


EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression.

Guasparri I, Bubman D, Cesarman E.

Blood. 2008 Apr 1;111(7):3813-20. doi: 10.1182/blood-2007-03-080309. Epub 2008 Jan 29. Erratum in: Blood. 2008 Jul 15;112(2):452.


A novel RING finger protein interacts with the cytoplasmic domain of CD40.

Hu HM, O'Rourke K, Boguski MS, Dixit VM.

J Biol Chem. 1994 Dec 2;269(48):30069-72.


Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation.

Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G.

Mol Cell Biol. 1996 Dec;16(12):7098-108.


Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein.

Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G.

Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11085-90.


Inhibition of tumor necrosis factor-induced phenotypes by short intracellular versions of latent membrane protein-1.

Ndour PA, Ouk TS, Brocqueville G, Mougel A, Vanhecke E, Feuillard J, Coll J, Adriaenssens E.

Cell Signal. 2010 Feb;22(2):303-13. doi: 10.1016/j.cellsig.2009.09.037. Epub 2009 Sep 29.


Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway.

Dudziak D, Kieser A, Dirmeier U, Nimmerjahn F, Berchtold S, Steinkasserer A, Marschall G, Hammerschmidt W, Laux G, Bornkamm GW.

J Virol. 2003 Aug;77(15):8290-8.

Supplemental Content

Support Center